As Chief Audit Officer of Novartis, Teresa and her team provide risk-based assurance and advice on key strategic topics to the Board and management, acting as a key partner to the organization to help ...

Sie suchen Kreativität und Innovation? Novartis bietet Ihnen das nötige Umfeld! Menschen, die uns mit ihrem Können und ihrer Erfahrung weiterbringen, können das Gleiche auch von uns erwarten. Think ...

We are excited to welcome the talented team at Regulus to Novartis as we continue to build on our pipeline in renal disease with high unmet medical need.” Farabursen is an investigational ...

Sie suchen Kreativität und Innovation? Novartis bietet Ihnen das nötige Umfeld! Menschen, die uns mit ihrem Können und ihrer Erfahrung weiterbringen, können das Gleiche auch von uns erwarten. Think ...

Novartis works with the patient community around the world to discover new ways to improve and extend people’s lives. Novartis works closely with healthcare professionals around the world to support ...

Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the ...

Job Title Sort ascending Business Location Site Date Posted; Višji strokovnjak za področje vizualne kontrole (m/ž/d) / Senior Visual Inspection Expert (m/f/d) Regulär, Full time Innovative Medicines ...

Positionsbezeichnung Sort ascending Business Standort Site Erscheinungsdatum; Višji strokovnjak za področje vizualne kontrole (m/ž/d) / Senior Visual Inspection Expert (m/f/d) Regulär, Full time ...

What is Novartis Managed Access? There are instances where a patient has a serious or life-threatening disease or condition, for which all currently available treatment options have been exhausted and ...

Careers at Novartis in Slovenia. At Novartis, we innovate, develop and operate on a vast scale. You can be part of it. Join our creative community of professionals and you will find opportunities to ...

Acquisition of Chinook Therapeutics, a clinical-stage biopharmaceutical company, completed for USD 3.2bn upfront; Deal brings two phase 3 assets in development for IgAN; atrasentan, an oral endothelin ...

Transaction to include pelabresib, a late-stage BET inhibitor for myelofibrosis (MF) and tulmimetostat, an early-stage investigational dual inhibitor of EZH2 and EZH1 for solid tumors or lymphomas; ...